Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2von Hippel-Lindau Disease 1Ulcer 1Smoldering Multiple Myeloma 1Skin Neoplasms 1Sarcoma, Kaposi 1Neoplasms 1Multiple Myeloma 1Melanoma 1Liver Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioma, Capillary 1Hemangioblastoma 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Bevacizumab 3Paclitaxel 2Lutetium-177 2Lutetium 2ribociclib 1repotrectinib 1regorafenib 1pembrolizumab 1palbociclib 1olaparib 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1camrelizumab 1atezolizumab 1apatinib 1Tretinoin 1Radiation 1Propranolol 1Imatinib Mesylate 1Hyperthermic Intraperitoneal Chemotherapy 1Fulvestrant 1Drug Therapy 1Clinical Trials, Phase II as Topic 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Digestive System Neoplasms × Propranolol × Clear all
NCT06775080 2025-01-14

The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors

Huashan Hospital

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡